Lede. Every advanced reactor the Department of Energy is currently subsidizing — NuScale's SMR-160, Oklo's Aurora, X-energy's Xe-100 — runs on HALEU: uranium enriched to 5-20% U-235, versus the ~4-5% that fuels today's light-water fleet. Russia's Rosatom is the only entity that has ever produced HALEU at commercial scale, and Congress banned Russian enriched uranium imports starting 2028. That leaves the DOE's HALEU Availability Program, created under the Energy Act of 2020, to manually bootstrap a domestic supply chain — and there is exactly one U.S. company licensed by the NRC to actually enrich it. This is a chokepoint trade: it doesn't matter which reactor vendor wins the advanced-nuclear race, because every one of them needs fuel from the same single domestic tap.
The HALEU Contract Nobody Prices In
DOE's HALEU Availability Program has exactly one NRC-licensed domestic enrichment beneficiary — making Centrus a chokepoint trade that pays out no matter which advanced reactor vendor wins.

| Ticker | Company | 1-year change |
|---|---|---|
| LEU | Centrus Energy | −54.3% |
| OKLO | Oklo | −64.4% |
| SMR | NuScale Power | −74.1% |
| CCJ | Cameco | +12.4% |
| CEG | Constellation Energy | −35.8% |
| VST | Vistra | −22.2% |
It doesn't matter which reactor vendor wins the advanced-nuclear race — every one of them needs fuel from the same single domestic tap.
Who cashes in:
Centrus Energy LEU is the whole story. Its American Centrifuge Plant in Piketon, Ohio is the first NRC-licensed HALEU enrichment facility in the country and the only one producing at scale — DOE extended Centrus's HALEU contract into a third phase through mid-2026 (worth roughly $110 million for that year alone, part of a contract structure with options running years further), after Centrus delivered 900 kg of HALEU to DOE, a stated "critical milestone." Every reactor developer that wins a DOE HALEU allocation round is, in practice, a future Centrus customer or beneficiary of Centrus-enriched material cascading through the program.
Oklo OKLO and NuScale SMR are the demand side of the same trade, not competitors to it. Both have been named among DOE's HALEU allocation rounds for advanced reactor developers. Their commercial timelines are entirely gated by fuel availability — meaning bullish Centrus capacity news (new cascades, new DOE contract phases) directly de-risks their build-out schedules, and delays at Piketon are a shared risk factor across both stocks.
BWXT benefits adjacently: it fabricates HALEU-based fuel forms (including for X-energy's TRISO-based designs and government/naval work) and sits downstream of Centrus in the enrichment-to-fuel-assembly chain, giving it leverage to the same buildout without single-supplier concentration risk.
Who is exposed:
Cameco CCJ mines and processes natural uranium and holds enrichment joint-venture stakes (via Westinghouse/BWXT-adjacent structures) but has no HALEU enrichment capacity of its own — it's exposed to being a price-taker in the one segment of the fuel cycle where the U.S. buildout is happening, while Russian-substitute demand concentrates value at the enrichment step, not the mining step.
Constellation CEG, Vistra VST, Talen TLN are utility/IPP plays on nuclear demand (uprates, restarts, AI data-center PPAs) but carry no direct HALEU exposure — they're a different trade entirely and shouldn't be conflated with the enrichment chokepoint.
The play: LEU is the purest, least crowded way to own the HALEU bottleneck itself, independent of reactor-vendor selection risk. Watch DOE energy.gov HALEU allocation announcements and Centrus 8-Ks for contract-phase exercises and new centrifuge cascade completions — each is a re-rating catalyst for LEU and a de-risking catalyst for OKLO/SMR simultaneously.
Source: original report ↗
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.